Clinical Trial Results:
Natalizumabbehandling af progressiv multipel sklerose
Summary
|
|
EudraCT number |
2009-016703-35 |
Trial protocol |
DK |
Global end of trial date |
26 Jan 2012
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
26 Jun 2022
|
First version publication date |
26 Jun 2022
|
Other versions |
|
Summary report(s) |
NAPMS summary |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
NAPMSv3.4
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01077466 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Danish Multiple Sclerosis Center, Rigshospitalet
|
||
Sponsor organisation address |
Valdemar Hansens Vej 13, Glostrup, Denmark, 2600
|
||
Public contact |
Per Soelberg Sørensen
Valdemar Hansens Vej 13
2600 Glostrup, Denmark, Danish Multiple Sclerosis Center, Rigshospitalet
Valdemar Hansens Vej 13
2600 Glostrup, Denmark, 0045 38633379, jeppe.romme.christensen@regionh.dk
|
||
Scientific contact |
Per Soelberg Sørensen
Valdemar Hansens Vej 13
2600 Glostrup, Denmark, Danish Multiple Sclerosis Center, Rigshospitalet
Valdemar Hansens Vej 13
2600 Glostrup, Denmark, 0045 38633406, pss@rh.dk
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
10 Dec 2013
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
26 Jan 2012
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
26 Jan 2012
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To study safety and efficacy of natalizumab treatment of primary and secondary progressive multiple sclerosis. This will be done by measuring the effect of treatment on inflammation in the CNS by means of osteopontin levels in the cerebrospinal fluid (CSF). Safety measures further includes physical and neurological exmination, blood samples and MRI measures of disease activity.
|
||
Protection of trial subjects |
Natalizumab is approved for the treatment of RRMS and is generally well tolerated. There is a known
risk of 1:1000 for developing progressive multifocal leukoencephalopathy (PML). All patients will be observed for the known side effects throughout the course of the trial and all side effects are recorded. It has been previously shown that natalizumab may reduce some of the inflammation seen in progressive MS. It is not possible to say whether this effect is synonymous with a positive effect on the course of the disease. There is no placebo group in the study, so all patients will have the opportunity to achieve a beneficial effect. Since there are few or no effective treatments for progressive MS, a positive result of this study will have great significance for the development of new treatments for progressive MS.
No patient will be deprived of active treatment. There is no approved treatment for PPMS. All patients participating in the study will be informed about the risk of known side effects, including the risk of PML, as well as the risk of unforeseen side effects in connection with drug trials. Participants in the trial will at can withdraw from the study any time. The study will be performed in accordance with the Helsinki Declaration of Biomedical research involving human individuals and ICH GCP. The potential beneficial effects of natalizumab in the treatment of progressive MS are estimated to outweigh the possible side effects. The rationale for the study is emphasized by the fact that only a few or no effective treatments for progressive MS and the outcome will be of great importance for patients, regardless of the outcome. Based on the above considerations, it is assessed that ethically, there is not arguments against performing the experiment.
|
||
Background therapy |
Mitoxantrone and interferon-beta are approved for the treatment of SPMS. Before the patient beginning the study, these treatment options will be discussed with the patient. | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
01 Mar 2010
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Denmark: 24
|
||
Worldwide total number of subjects |
24
|
||
EEA total number of subjects |
24
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
24
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||
Recruitment
|
|||||||||||||
Recruitment details |
Study Start Date : March 2010 Actual Primary Completion Date: January 2012 Actual Study Completion Date: January 2012 | ||||||||||||
Pre-assignment
|
|||||||||||||
Screening details |
Inclusion Criteria: Age between 19 and 55 years Progressive disease course of multiple sclerosis (primary or secondary) Duration of progressive phase of at least 1 year Progression of > 1 EDSS point during the last 2 years (>½ EDSS point if EDSS > 5,5) EDSS </= 6.5 Written and informed consent | ||||||||||||
Period 1
|
|||||||||||||
Period 1 title |
Overall trial (overall period)
|
||||||||||||
Is this the baseline period? |
Yes | ||||||||||||
Allocation method |
Not applicable
|
||||||||||||
Blinding used |
Not blinded | ||||||||||||
Arms
|
|||||||||||||
Arm title
|
Open label uncontrolled | ||||||||||||
Arm description |
300 mg Natalizumab IV for every 4 week for 56 weeks (15 doses for every patient). | ||||||||||||
Arm type |
Experimental | ||||||||||||
Investigational medicinal product name |
natalizumab
|
||||||||||||
Investigational medicinal product code |
AN100226
|
||||||||||||
Other name |
Tysabri
|
||||||||||||
Pharmaceutical forms |
Solution for injection/infusion
|
||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||
Dosage and administration details |
300 mg every 4 week
|
||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Overall trial
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis sets
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
NAPMS
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Full analysis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
The included patients in the NAPMS trial were 12 secondary progressive MS patients (SPMS) and 12 primary progressive MS (PPMS) patients. Female/male ratio was 7/5 for SPMS and 6/6 for PPMS. Median (range) age was 44 (36-53) for SPMS and 48 (27-55) for PPMS. Disease duration 14 years for SPMS and 4 years for PPMS. Median EDSS was 5.25 for SPMS and 5.0 for PPMS.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
NAPMS completed
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Per protocol | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
17 patients completed the study
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Open label uncontrolled
|
||
Reporting group description |
300 mg Natalizumab IV for every 4 week for 56 weeks (15 doses for every patient). | ||
Subject analysis set title |
NAPMS
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
The included patients in the NAPMS trial were 12 secondary progressive MS patients (SPMS) and 12 primary progressive MS (PPMS) patients. Female/male ratio was 7/5 for SPMS and 6/6 for PPMS. Median (range) age was 44 (36-53) for SPMS and 48 (27-55) for PPMS. Disease duration 14 years for SPMS and 4 years for PPMS. Median EDSS was 5.25 for SPMS and 5.0 for PPMS.
|
||
Subject analysis set title |
NAPMS completed
|
||
Subject analysis set type |
Per protocol | ||
Subject analysis set description |
17 patients completed the study
|
|
|||||||||||||
End point title |
Cerebrospinal fluid osteopontin | ||||||||||||
End point description |
Mean change in CSF osteopontin from baseline to week 60
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Baseline (week 0) to week 60
|
||||||||||||
|
|||||||||||||
Attachments |
CSF endpoints |
||||||||||||
Notes [1] - Analysis made on the 17 patients completing the trial |
|||||||||||||
Statistical analysis title |
CSF osteopontin change | ||||||||||||
Comparison groups |
Open label uncontrolled v NAPMS completed
|
||||||||||||
Number of subjects included in analysis |
34
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
other [2] | ||||||||||||
P-value |
= 0.0004 | ||||||||||||
Method |
t-test, 2-sided | ||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||
Point estimate |
65
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
34 | ||||||||||||
upper limit |
96 | ||||||||||||
Variability estimate |
Standard deviation
|
||||||||||||
Dispersion value |
60
|
||||||||||||
Notes [2] - Single-arm longitudinal. Paired T-test. |
|
|||||||||
End point title |
Cerebrospinal fluid CXCL13 | ||||||||
End point description |
Mean change from baseline to week 60.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Baseline to week 60
|
||||||||
|
|||||||||
Notes [3] - Analysis made on the 17 patients who completed the study |
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Cerebrospinal fluid MMP9 | ||||||||
End point description |
Mean change from baseline to week 60
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Baseline to week 60
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Cerebrospinal fluid neurofilament light chain | ||||||||
End point description |
Mean change from baseline to week 60
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Baseline to week 60
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Cerebrospinal fluid myelin basic protein | ||||||||
End point description |
MEan change from baseline to week 60
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Baseline to week 60
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Percentage brain volume change | ||||||||
End point description |
Change in percentage normalised brain volume from week 12 to week 60
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Week 12 to week 60
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Normal apperaing white matter volume | ||||||||
End point description |
Change in normal appearing white matter volume from week 12 to week 60
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Week 12 to week 60
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Grey matter volume | ||||||||
End point description |
Change in grey matter volume (GMV) from week 12 to week 60
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Week 12 to week 60
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||
End point title |
Number of new lesions on T2-weighted MRI images | ||||||
End point description |
|||||||
End point type |
Secondary
|
||||||
End point timeframe |
Baseline to week 60
|
||||||
|
|||||||
No statistical analyses for this end point |
|
|||||||
End point title |
Number of enlarging lesions on T2-weighted MRI images | ||||||
End point description |
|||||||
End point type |
Secondary
|
||||||
End point timeframe |
Baseline to week 60
|
||||||
|
|||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Volume of lesions on T2-weighted MRI images | ||||||||
End point description |
|||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Baseline to week 60
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Magnetization transfer ratio (MTR) in NAWM | ||||||||
End point description |
|||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Baseline to week 60
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Magnetization transfer ratio (MTR) in grey matter | ||||||||
End point description |
|||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Baseline to week 60
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Magnetization transfer ratio (MTR) lesions | ||||||||
End point description |
|||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Baseline to week 60
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
EDSS change | ||||||||
End point description |
|||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Baseline to week 60
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Timed 25 foot walk | ||||||||
End point description |
|||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Baseline to week 60
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
9 hole peg test | ||||||||
End point description |
|||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Baseline to week 60
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Baseline to week 60
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
ICD10 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
2010
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Open label uncontrolled
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
300 mg Natalizumab IV for every 4 week for 56 weeks (15 doses for every patient). | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 4% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported | |||
Online references |
|||
http://www.ncbi.nlm.nih.gov/pubmed/24682973 |